Navigation Links
Genomma Lab Internacional Acquires Brands Flor de Naranja Sanborns(MR), Teatrical and Henna Egipcia From Grupo Sanborns

- These acquisitions reinforce Genomma Lab's presence in the cosmetics and hair product categories and mark the Company's entrance into the lotions and perfumes segments

- Genomma Lab continues the acquisition program announced during the Company's public offering, which took place in June 2008

MEXICO CITY, June 5 /PRNewswire-FirstCall/ -- Genomma Lab Internacional S.A.B. DE C.V. (BMV: LAB) ("Genomma Lab" or "the Company"), one of the largest and most diversified Mexican companies in the pharmaceutical and personal care products categories, announced the acquisition of the brand of lotions Flor de Naranja Sanborns(MR), the brand properties for Teatrical creams, Henna Egipcia hair color, and a 99 year license for the use of Sanborns(MR) brands from the acquired brands.

With this acquisition, Genomma Lab strengthens its presence in the face cream and body lotions markets as well as hair products categories, while expanding its offering of lotion and perfume products. Sales for the acquired brands reached Ps. 110.3 million during the trailing twelve months ended April 30, 2009.

Teatrical is a traditional and popular brand in Mexico. Registered for sale since 1928, its range of face creams and body lotions has been on the minds of several generations of consumers for over 80 years.

Cologne water Flor de Naranja Sanborns(MR) has an 82-year trajectory and is also one of the most recognized brands in its market segment.

Finally, Henna Egipcia is a recognized brand of discreet hair color products with a nearly 45-year history in the marketplace.

"These acquisitions are in line with the Company's growth strategy implemented since the public offering, which includes the generation and acquisition of new brands and products in order to increase its presence in the medicinal and personal care products markets," stated Mr. Rodrigo Herrera, Chief Executive Officer.

Genomma Lab seeks to revitalize its acquired brands and strengthen its expansion via the application of its business model.

Genomma Lab paid for this transaction with its own resources at a multiple of 2.7x sales for the trailing twelve months for a total of Ps. 300 million, of which approximately 50% will be paid in 10 payments over 10 years.

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is a leading over-the-counter pharmaceuticals and personal care products company in Mexico with international presence. Genomma develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share.

The Company is listed on the Mexican Stock Exchange under the ticker symbol "LAB.B" (Bloomberg:

Web Site:

SOURCE Genomma Lab Internacional, S.A.B. de C.V.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genomma Lab Internacional Announces First Quarter 2009 Results
2. Genomma Lab Acquires the Mexican Company Medicinas y Medicamentos Nacionales
3. Genomma Lab Internacional Announces Fourth Quarter and Full Year 2008 Results
4. Webcast Alert: Genomma Lab Announces Fourth Quarter 2008 Earnings Webcast
5. Genomma Lab Announces Updated Fourth Quarter 2008 Guidance
6. Genomma Lab, New Participant in Market-Maker Program
7. Genomma Lab Announces Initiation of Stock Repurchase Fund
8. Genomma Lab Announces the Successful Launch of the Ma Evans Brand
9. Genomma Lab Announces 2009 Earnings Guidance
10. Genomma Lab Internacional Acquires UNIGASTROZOL
11. Webcast Alert: Genomma Lab Internacional, S.A.B. de C.V. announces Second Quarter 2008 Results Conference Call
Post Your Comments:
(Date:11/24/2015)... ... November 24, 2015 , ... ... it comes to several aspects of orthopedic care. They have received recognition for ... and general orthopedic care. , Becker's Hospital Review selected hospitals for inclusion ...
(Date:11/24/2015)... ... November 24, 2015 , ... It takes only three to ... it is critical that the first impression be positive and reflects business values. If ... to buy anything or want to return. They will also share their thoughts about ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... LENR HHT Bolier Reactor System. Brillouin is the developer of renewable energy technologies ... low energy nuclear reactions (“LENR”), announced today that its WET™ and HHT™ Boiler ...
(Date:11/24/2015)... (PRWEB) , ... November 24, 2015 , ... ... advisory organization, is pleased to welcome Winter-Dent & Company as its newest Partner ... day one to become a client's most trusted advisor regardless of whether that ...
(Date:11/24/2015)... ... November 24, 2015 , ... ... States to support their local poison centers through donations on Tuesday, Dec. 1, ... calls it “a day that inspires people to collaborate in improving their local ...
Breaking Medicine News(10 mins):
(Date:11/24/2015)... , Nov. 24, 2015  Family Rentals, a ... announced the launch of their newly designed, mobile-responsive ... --> Logo ... --> --> Now, renting essential ... and vacation, just got a whole lot easier ...
(Date:11/24/2015)... --> --> Opportunities ... and PPAR Agonists cholesterol-lowering drugs market ? ... rates? This visiongain report shows you potential ... there. ,  ,Our 199-page report provides 153 tables, charts, ... industry and the future market prospects. Our new study ...
(Date:11/24/2015)... , Nov. 24, 2015  Boston Scientific Corporation (NYSE: ... Oppenheimer 26th Annual Healthcare Conference on December 8, in ... Susie Lisa , vice president, Investor Relations, will participate ... beginning at approximately 8:35 a.m. ET. --> ... in a 30-minute question-and-answer session with the host analyst ...
Breaking Medicine Technology: